The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.
Histone deacetylase inhibitors (HDACis) are currently in trial or are in clinical use for the treatment of a number of tumor types. The clinical efficacy of HDACis can be partly attributed to the modulation of the cell cycle by the HDACis. Here, we have examined the effects of N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide (MGCD0103), a class I-selective histone deacetylase inhibitor, on the cell cycle and cell killing. Surprisingly, MGCD0103 treatment failed to initiate a G(1)-phase arrest but caused marked accumulation of cells in G(2)/M at 6 and 12 h after treatment and was cytotoxic 24 h after treatment. These cell cycle effects were considerably distinct from the effects of suberic bishydroxamic acid, a representative of the pan-isoform HDACi used in this study. MGCD0103 shared the ability of the pan-isoform HDACi to trigger defective mitosis and promote mitotic slippage. Likewise, it also specifically targeted tumor cells and was nontoxic to normal nontransformed cells. However, MGDC0103 also seemed to disrupt normal microtubule spindle formation, whereas HDACis generally have only a minor effect on spindle formation. The effect of MGCD0103 on spindle formation was shown to be a consequence of microtubule destabilization. This is the first example of an HDACi with microtubule destabilizing activity, and the combined effects of this drug have advantages for its therapeutic use.
University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Keeming
K
Chia
Heather
H
Beamish
Kaneez
K
Jafferi
Brian
B
Gabrielli
D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008870:Microtubules / Q000378:metabolism / Q000473:pathology; D008938:Mitosis / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D011743:Pyrimidines; D050257:Tubulin Modulators / Q000494:pharmacology / Q000627:therapeutic use
D001549:Benzamides; D056572:Histone Deacetylase Inhibitors; D011743:Pyrimidines; D050257:Tubulin Modulators; C037689:benzamide; C523184:mocetinostat; D006655:Histone Deacetylases